NCT00703183

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of a new investigational drug (ACU-4429) in healthy human volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P50-P75 for phase_1 healthy

Timeline
Completed

Started May 2008

Longer than P75 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 19, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 23, 2008

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

June 27, 2012

Status Verified

June 1, 2012

Enrollment Period

1.1 years

First QC Date

June 19, 2008

Last Update Submit

June 25, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety and tolerability

    7 days

Secondary Outcomes (1)

  • Pharmacokinetics

    2 days

Study Arms (2)

1

EXPERIMENTAL

ACU-4429

Drug: ACU-4429

2

PLACEBO COMPARATOR

matching placebo

Drug: matching placebo

Interventions

administered as a single dose, orally

1

administered as a single dose, orally

2

Eligibility Criteria

Age55 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Is male or female with age ≥ 55 and ≤ 80 years at the time of consent
  • Is healthy as determined by medical history and physical examination

You may not qualify if:

  • Is receiving or has recently received treatment with a medication disallowed per the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Covance Clinical Research Unit, Inc

Dallas, Texas, 75247, United States

Location

MeSH Terms

Interventions

emixustat

Study Officials

  • William W Lewis, M.D.

    Covance

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2008

First Posted

June 23, 2008

Study Start

May 1, 2008

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

June 27, 2012

Record last verified: 2012-06

Locations